T
The New York Times
Guest
The Omicron variant of the coronavirus is incredibly contagious — it is able to infect people with even greater frequency than the Delta variant, and it is skilled at evading the immune system’s defenses. Much is still unknown about the new variant, and scientists are racing to understand its threat. But amid the uncertainty, there’s good news about a prospective new virus treatment: A pill by Pfizer is effective in reducing people’s risk of hospitalization or death from Covid-19.
We explore these two developments and what they could mean for the next phase of the pandemic.
Guest: Carl Zimmer, a science writer and author of the “Matter” column for The New York Times.
Sign up here to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter.
Background reading:
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
Continue reading...
We explore these two developments and what they could mean for the next phase of the pandemic.
Guest: Carl Zimmer, a science writer and author of the “Matter” column for The New York Times.
Sign up here to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter.
Background reading:
- An Omicron surge is likely. Here’s what to expect.
- Pfizer announced that its Covid pill was found to stave off severe disease in a key clinical trial and that it is likely to work against the highly mutated Omicron variant of the virus.
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
Continue reading...